# OnCo record paper-aza-aml-001-dombret-blood-2015 (paper). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/key-papers/paper-aza-aml-001-dombret-blood-2015/>
  a schema:ScholarlyArticle ;
  onco:kind "paper" ;
  schema:identifier "paper-aza-aml-001-dombret-blood-2015" ;
  schema:name "AZA-AML-001: azacitidine versus conventional care in older patients with acute myeloid leukaemia and more than 30 percent blasts"@en ;
  schema:description "In older people with acute myeloid leukaemia who were not good candidates for intensive chemotherapy, azacitidine lengthened median survival by about four months compared with the usual options and became the backbone that venetoclax was later added to."@en ;
  schema:url <https://onco.cc/key-papers/paper-aza-aml-001-dombret-blood-2015/> ;
  schema:dateModified "2026-09-17"^^xsd:date ;
  schema:citation <https://doi.org/10.1182/blood-2015-01-621664>, <https://pubmed.ncbi.nlm.nih.gov/25987659/> ;
  schema:sameAs <https://doi.org/10.1182/blood-2015-01-621664> ;
  schema:datePublished "2015"^^xsd:gYear ;
  schema:author "Dombret H, Seymour JF, Butrym A, et al." ;
  onco:cancers <https://onco.cc/cancers/aml-older-unfit/> ;
  onco:drugs <https://onco.cc/drugs/azacitidine/> ;
  onco:journals <https://onco.cc/journals/blood/> .